Milbemycin oxime
Based on 1 publication(s) in Google Scholar
Milbemycin oxime is an orally active macrolide with broad-spectrum antiparasitic activity. Milbemycin oxime is a mixture of oximes consisting of oxime derivatives corresponding to milbemycin A4 and A3. Milbemycin oxime binds to glutamate-gated chloride channels and has inhibitory potency against intestinal nematodes and lung/heart worms.
For research use only. We do not sell to patients.
- Purity: 99.42%
- CAS No.: 129496-10-2
- Formula: C63H88N2O14
- Molecular Weight:1097.38
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Natural Product Library
HY-L021
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Antiparasitic Compound library
HY-L082
-
Microbial Metabolite Library
HY-L084
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Animal Drug Library
HY-L218
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Milbemycin oxime
MoreAll Antibiotic Isoforms
MoreAll Parasite Isoforms
More
Biological Activity
|
Macrolide |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Angiostrongylus vasorum infected dogs[3]
-
Dosage:0.5 g, 1 g, and 2 g containing 9.375 mg + 1.875 mg, 18.75 mg + 3.75 mg, and 37.5 mg + 7.5 mg .
-
Administration:p.o., on study days 0, 28, 56 and 84 with a combination of Afoxolaner plus Milbemycin oxime chewable tablets.
-
Result:Reduced the geometric mean worm count and geometric mean faecal larval counts in the treated group.
Chemical Information
-
CAS No. 129496-10-2
-
Appearance Solid
-
Molecular Weight 1097.38
-
Formula C63H88N2O14
-
Color White to off-white
-
SMILES
CC1=C[C@@H]2[C@@]3(O)[C@H](OC/C3=C\C=C\[C@H](C)C/C(C)=C/C[C@@H](O[C@@]4(CC[C@H](C)[C@@H](C)O4)C5)C[C@@H]5OC2=O)/C1=N\O.CC6=C[C@@H]7[C@@]8(O)[C@H](OC/C8=C\C=C\[C@H](C)C/C(C)=C/C[C@@H](O[C@@]9(CC[C@H](C)[C@@H](CC)O9)C%10)C[C@@H]%10OC7=O)/C6=N\O
-
Structure Classification
-
Initial Source
Streptomyces hygroscopicus
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Mol Ther
Reprogramming tumor immune microenvironment by milbemycin oxime results in pancreatic tumor growth suppression and enhanced anti-PD-1 efficacy. [Abstract]2024 Aug 2:S1525-0016(24)00522-7. PMID: 39097773
Solvent & Solubility
DMSO : ≥ 100 mg/mL (91.13 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (2.28 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (1.90 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (761 KB)
- English - EN (761 KB)
- Français - FR (761 KB)
- Deutsch - DE (761 KB)
- Norwegian - NO (761 KB)
- Español - ES (761 KB)
- Swedish - SV (761 KB)
- Italian - IT (761 KB)
- Korean - KR (761 KB)
- Portuguese - PT (761 KB)
-
Handling Instructions (2659 KB)
References
[1]. Valentina M Merola, et al. Toxicology of avermectins and milbemycins (macrocylic lactones) and the role of P-glycoprotein in dogs and cats. Vet Clin North Am Small Anim Pract. 2012 Mar;42(2):313-33, vii. [Content Brief]
[2]. Dejan Cvejic, et al. Efficacy of a single dose of milbemycin oxime/praziquantel combination tablets, Milpro(®), against adult Echinococcus multilocularis in dogs and both adult and immature E. multilocularis in young cats. Parasitol Res. 2016 Mar;115(3):1195-202. [Content Brief]
[3]. Lebon W, et al. Monthly administrations of milbemycin oxime plus afoxolaner chewable tablets to prevent Angiostrongylus vasorum infection in dogs. Parasit Vectors. 2016 Sep 2;9(1):485. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 0.9113 mL | 4.5563 mL | 9.1126 mL | 22.7815 mL |
| 5 mM | 0.1823 mL | 0.9113 mL | 1.8225 mL | 4.5563 mL | |
| 10 mM | 0.0911 mL | 0.4556 mL | 0.9113 mL | 2.2782 mL | |
| 15 mM | 0.0608 mL | 0.3038 mL | 0.6075 mL | 1.5188 mL | |
| 20 mM | 0.0456 mL | 0.2278 mL | 0.4556 mL | 1.1391 mL | |
| 25 mM | 0.0365 mL | 0.1823 mL | 0.3645 mL | 0.9113 mL | |
| 30 mM | 0.0304 mL | 0.1519 mL | 0.3038 mL | 0.7594 mL | |
| 40 mM | 0.0228 mL | 0.1139 mL | 0.2278 mL | 0.5695 mL | |
| 50 mM | 0.0182 mL | 0.0911 mL | 0.1823 mL | 0.4556 mL | |
| 60 mM | 0.0152 mL | 0.0759 mL | 0.1519 mL | 0.3797 mL | |
| 80 mM | 0.0114 mL | 0.0570 mL | 0.1139 mL | 0.2848 mL |
Milbemycin oxime Related Classifications
HY-B0778 Related Classifications
Powered by Bioz